2 unknown, 1 recruiting, 1 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 2, Recruiting 1, Terminated 1 |
Follow Cardiac Event: new trials by email Literature Review of Cardiac Event trials Research Report on Cardiac Event
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage Xenon, air/oxygen - Subarachnoid Hemorrhage, Aneurysmal, Cerebral Injury | Phase 2 | Recruiting | Turku University Hospital | 160 | 2025-04-22 | 2025-05-01 |
| Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
| Cardiovascular Events in GnRH Agonist vs. Antagonist Degarelix, GnRH agonist - Hormone Sensitive Prostate Cancer, Prostate Cancer | Phase 2 | Unknown | Rabin Medical Center | 80 | 2020-01-17 | 2019-12-02 |
| Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer Xinmailong Injection - Breast Neoplasms, Cardiac Event | Phase 2 | Unknown | Peking Union Medical College | 60 | 2019-01-01 | 2020-01-22 |
Cardiovascular Diseases (4) · Heart Failure (2) · Brain Injuries (1) · Brain Ischemia (1) · Breast Neoplasms (1) · COVID-19 (1) · Cerebral Infarction (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Dyspnea (1) · Myocardial Infarction (1) · Pneumonia (1) · Prostatic Neoplasms (1) · Pulmonary Edema (1) · Respiratory Distress Syndrome (1)
Heart Diseases (2) · Infarction (2) · Ischemia (2) · Necrosis (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Vascular Diseases (2) · Brain Diseases (1) · Brain Infarction (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Coronaviridae Infections (1)
Gonadotropin-Releasing Hormone (1) · VIP-ELP fusion molecule PB1046 (1) · Xenon (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · xinmailong (1)
Peking Union Medical College (1) · PhaseBio Pharmaceuticals Inc. (1) · Rabin Medical Center (1) · Turku University Hospital (1)
China (1) · Finland (1) · Israel (1) · Sweden (1) · United States (1)
David Margel, MD, PhD (1) · Timo T Laitio, MD, PhD (1)
PMID 26978207, PMID 29169472, PMID 34350976, PMID 37337295
2019 (1)